Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

NCT00141843 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

GENETIC: ReFacto AF
GENETIC: B-Domain deleted Recombinant Factor VIII
GENETIC: BDDrFVIII

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer